v3.26.1
Unaudited Condensed Consolidated Interim Statements of Changes in Capital Deficiency (Equity) and Capital Deficiency - USD ($)
$ in Thousands
Series Y Redeemable Convertible
Preferred Shares
Series X Redeemable Convertible
Preferred Shares
Redeemable Convertible Preferred Shares
Preferred Shares
Common stock
Additional paid-in capital
Accumulated Other Comprehensive Income (Loss)
Accumulated deficit
Receivables on account of shares
Non-Controlling interests
Total
Balance at Dec. 31, 2024     $ 18,645 $ 6 $ 186,194   $ (180,697)     $ 24,148
Balance (in Shares) at Dec. 31, 2024     147,735 18,176,661 [1]            
Stock-based compensation expenses       659         659
Net loss           (7,659)     (7,659)
Issuance of Common Stock, Registered Pre- Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs     [2] 878       878
Issuance of Common Stock, Registered Pre- Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs (in Shares)     2,828,283 [1]            
Issuance of Common Stock under Inducement Letter Agreements     $ 1 6,472         6,473
Issuance of Common Stock under Inducement Letter Agreements (in Shares)     3,961,109 [1]            
Balance at Mar. 31, 2025     $ 18,645 $ 7 194,203   (188,356)     24,499
Balance (in Shares) at Mar. 31, 2025     147,735 24,966,053 [1]            
Balance at Dec. 31, 2024     $ 18,645 $ 6 186,194   (180,697)     24,148
Balance (in Shares) at Dec. 31, 2024     147,735 18,176,661 [1]            
Net loss                   (13,696)
Balance at Jun. 30, 2025     $ 18,645 $ 7 194,901   (194,393)     19,160
Balance (in Shares) at Jun. 30, 2025     147,735 26,443,257 [1]            
Balance at Mar. 31, 2025     $ 18,645 $ 7 194,203   (188,356)     24,499
Balance (in Shares) at Mar. 31, 2025     147,735 24,966,053 [1]            
Stock-based compensation expenses         696         696
Net loss             (6,037)     (6,037)
Exercise of Private Pre-Funded Warrants and Common Warrants       [2] 2         2
Exercise of Private Pre-Funded Warrants and Common Warrants (in Shares) [1]       1,202,314            
Issuance of Common Stock upon restricted stock units vesting [2]                
Issuance of Common Stock upon restricted stock units vesting (in Shares) [1]       274,890            
Balance at Jun. 30, 2025     $ 18,645 $ 7 194,901   (194,393)     19,160
Balance (in Shares) at Jun. 30, 2025     147,735 26,443,257 [1]            
Balance at Dec. 31, 2025 $ 18,617   $ 7 196,970 (216,896) (1,302)
Balance (in Shares) at Dec. 31, 2025 147,512   1,593,703            
Issuance of Series Y Convertible Preferred Stock  
Issuance of Series Y Convertible Preferred Stock (in Shares) 3,300              
Preferred dividends on Series Y Convertible Preferred Stock $ 85   (85)  
Conversion of Series Y Convertible Preferred Stock into common stock $ (85)   [2] 85
Conversion of Series Y Convertible Preferred Stock into common stock (in Shares) (3,300)   1,650,000            
Exercise of warrants into common stock   [2] 16,785 (3,300) 13,485
Exercise of warrants into common stock (in Shares)   3,300,000            
Reclassification of embedded conversion derivative upon conversion of Series Y Convertible Preferred Stock   7,818   7,818
Stock-based compensation expenses   (1,742)   (1,742)
Net loss   (19,140)   (19,140)
Balance at Mar. 31, 2026 $ 18,617   $ 7 219,831 (236,036) (3,300) (881)
Balance (in Shares) at Mar. 31, 2026 147,512   6,543,703            
Balance at Dec. 31, 2025 $ 18,617   $ 7 196,970 (216,896) (1,302)
Balance (in Shares) at Dec. 31, 2025 147,512   1,593,703            
Net loss                   (22,986)
Balance at Jun. 30, 2026 $ 6,512   $ 8 244,474 (21) (239,808) (300) 6,758 17,623
Balance (in Shares) at Jun. 30, 2026 51,598   12,590,641            
Balance at Mar. 31, 2026 $ 18,617   $ 7 219,831 (236,036) (3,300) (881)
Balance (in Shares) at Mar. 31, 2026 147,512   6,543,703            
Stock-based compensation expenses     $ 1 3,987 3,988
Stock-based compensation expenses (in Shares)     1,380,000            
Net loss   (3,772)   (74) (3,846)
Issuance of shares for investment in Zorronet     [2] 3,757 3,757
Issuance of shares for investment in Zorronet (in Shares)                
Issuance of warrants and shares for investment in DFSL     [2] 4,124 4,124
Issuance of warrants and shares for investment in DFSL (in Shares)     923,000            
Issuance of shares as partial payment of promissory note     [2] 379 379
Issuance of shares as partial payment of promissory note (in Shares)     1,013,637            
Issuance of Common Stock under At the Market Sales Agreement, net of $ 39 issuance costs     [2] 291 291
Issuance of Common Stock under At the Market Sales Agreement, net of $ 39 issuance costs (in Shares)                
Offset of promissory note           3,000 3,000
Subsidiaries consolidation for the first time             6,818 6,818
Foreign currency translation adjustments         (21)     14 (7)
Conversion of A&R Warrants     [2] [2]    
Conversion of A&R Warrants (in Shares)     132,484            
Conversion of Series X Redeemable Convertible Preferred Shares $ (12,105)   [2] 12,105    
Conversion of Series X Redeemable Convertible Preferred Shares (in Shares) (95,914)   504,812            
Balance at Jun. 30, 2026 $ 6,512   $ 8 $ 244,474 $ (21) $ (239,808) $ (300) $ 6,758 $ 17,623
Balance (in Shares) at Jun. 30, 2026 51,598   12,590,641            
[1] All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 8A.
[2] Less than $1.